Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Zimmer/Implex

This article was originally published in The Gray Sheet

Executive Summary

Strategic sales and marketing alliance between Bristol-Myers Squibb's Zimmer subsidiary and privately held Implex gives Zimmer exclusive worldwide distribution rights to Implex's Hedrocel joint reconstruction products. The alliance allows Implex to retain rights to spine and sports medicine products, although Zimmer has the sole right to acquire the entire Implex business at a later date, company reps note. Implex is in the process of submitting an investigational device exemption to FDA for a lumbar interbody fusion device. A cervical interbody fusion device was granted IDE status several months ago. Both devices have received CE marks and are being marketed overseas in a targeted release while Implex lines up distribution in Europe. Previously, Zimmer-competitor Sofamor Danek had licensed the Hedrocel technology, but that deal was scuttled (1"The Gray Sheet" March 30, 1998, p. 21)
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT013776

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel